Shots:

• Endocyte to receive $24M/share in cash with total deal value of $2.1B. Novartis to get hold of all stocks with its RLT candidates Lu-PSMA-617 & Ac-PSMA-617
• Lu-PSMA-617 is a novel treatment currently evaluated globally in P-III VISION clinical trial in men with mCRPC and demonstrated positive results in P-II (N=50) with mPFS (7.6 mos) & mOS (13.5 mos) in mCRPC
• Additionally- Novartis gained rights for Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) with acquisition of AAA- a novel approved Peptide Receptor Radionuclide Therapy for GEP-NETs

Ref: Novartis | Image: RTE